Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Indexes  >  Swiss Exchange  >  SMI    SMI   CH0009980894

Indicative prices
Mes dernières consult.
Most popular
News SummaryAll newsNews of the components ofTweets
News of the components of SMI
12:14p UBS : #17-45 Update of CFI and FISN codes for instruments issued by UBS AG
11:14a LAFARGEHOLCIM : supplies high-performance concrete for the European XFEL super l..
10:19a ABB : pioneers microgrid solution for installation on offshore platform
07:11a ZURICH INSURANCE : Agrees to australian tie-up
12/11 ROCHE : Histone modifier is implicated in epithelial-mesenchymal transition
12/11DJZurich to Buy ANZ's Australian Life Insurance Business
12/11 ZURICH INSURANCE : enters agreement to acquire ANZ’s life insurance busine..
12/11 HOT SOURCE ISSUE 17 : Festive Foods, FSSC 22000 updates, EU Food Waste Guideline..
12/11 NOVARTIS : drug crizanlizumab shown to prolong time to patients' first sickle ce..
12/11 SGS : EU Nutrition and Health Claims on Food Labeling – Update
12/11 SGS : Food Redistribution Guidelines to Tackle Wastage Across the EU
12/11 SGS : Food Safety for the Holiday Season
12/11 SGS : IFIA Publishes 2016 Food Fraud and Traceability Survey
12/11 SGS : Agriculture and Food Testing Laboratory in Brookings, South Dakota
12/11 SGS : Blockchain Technology Increases Supply Chain Security
12/11 SGS : What’s New in FSSC 22000 version 4.1?
12/11 UBS : Barclays, Credit Suisse, KBC, SIX, Thomson Reuters and UBS collaborate to ..
12/11 ROCHE : Genentech's HEMLIBRA Every Four Weeks Controlled Bleeds in Phase III Stu..
12/11 ROCHE : Genentech - Phase III IMpower150 Study Showed Tecentriq and Avastin Plus..
12/11 CREDIT SUISSE : CARE Selects Fides Treasury Services for End-to-End Global Bank ..
12/11 ZURICH INSURANCE : A.M. Best Revises Outlooks to Stable for Zurich Insurance Gro..
12/11 ROCHE : Phase III IMmotion151 study showed Roche's Tecentriq (atezolizumab) and ..
12/11 ROCHE : Phase II data showed Roche's investigational polatuzumab vedotin plus be..
12/11 ROCHE : Meeting access challenges with adaptive trial designs
12/11 NESTLE : Blue Bottle Coffee coming to Seoul in March
12/11DJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
12/11 JULIUS BÄR GRUPPE : Baer ‍nominates Campbell-Breeden for board seat
12/11 ROCHE : Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab..
12/11 Julius Baer Group Ltd. nominates Richard M. Campbell-Breeden for election to ..
12/11 JULIUS BÄR GRUPPE : Baer Group Ltd. nominates Richard M. Campbell-Breeden for el..
12/11 ROCHE : Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezoliz..
12/11 SGS : California Proposition 65 Reformulation of DEHP in Consumer Products
12/11 GENENTECH : Polatuzumab Vedotin Plus Bendamustine And Rituxan Increased CR Rates
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/10 NOVARTIS : Primary analysis results from Novartis pivotal JULIET trial show Kymr..
12/10 ROCHE : Phase II data showed Roche’s investigational polatuzumab vedotin p..
12/10 ROCHE : Phase II Data Showed Genentech’s Investigational Polatuzumab Vedot..
12/10 ZURICH INSURANCE : Thanking America's teachers
12/09 ROCHE : Hemlibra continued to substantially reduce bleeds in people with haemoph..
12/09 GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduc..
12/09 LAFARGEHOLCIM : Two Swiss-French firm officials charged with financing Daesh in ..
12/09 NOVARTIS : $32,000 Federal Contract Awarded to Alcon Laboratories
12/09 ZURICH INSURANCE : Turkey Giveaways at Edinburg Housing Authority
12/09 ZURICH INSURANCE : distributes gift cards to needy families
12/08 NESTLE : Prairie Adventures
12/08 LAFARGEHOLCIM : Former Lafarge CEO under investigation in Syria payments case
12/08DJROCHE : Novartis's Italian Heads Risk Trial for Alleged Market Rigging -Reuters
12/08 LAFARGEHOLCIM : FRANCE-SYRIA - Former LafargeHolcim CEO charged in terror financ..
12/08 ROCHE : s haemophilia A drug shows meaningful bleed control in P3
Chart SMI
Duration : Period :
SMI Technical Analysis Chart | SMI | CH0009980894 | 4-Traders
Technical analysis trends SMI
Short TermMid-TermLong Term
Top / Flop SMI
LONZA GROUP 259.3 Delayed Quote.0.86%
SGS 2474 Delayed Quote.0.65%
UBS GROUP 17.64 Delayed Quote.0.46%
NESTLÉ 85.2 Delayed Quote.0.24%
NOVARTIS 83.2 Delayed Quote.0.24%
SWISSCOM 516.5 Delayed Quote.-0.29%
SWISS LIFE HOLDING 331.7 Delayed Quote.-0.33%
LAFARGEHOLCIM 52.4 Delayed Quote.-0.38%
ABB LTD 25.65 Delayed Quote.-0.39%
THE SWATCH GROUP 384.6 Delayed Quote.-0.57%
Heatmap :